Connolly, Denise C.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 145

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · Cancer Research

DNA Repair MechanismsBreast Cancer Treatment Studies

Cited by 54

Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors

Lara, H., Wang, Y., Beltran, A. S., Juárez-Moreno, K., Yuan, X., Kato, S., Leisewitz, A. V., Cuello Fredes, M., Licea, A. F., Connolly, D. C., et al. (2012) · Journal of Biological Chemistry

RNA Interference and Gene DeliveryOvarian cancer diagnosis and treatment

Cited by 42

Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype

Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics

Ovarian cancer diagnosis and treatmentCancer Mechanisms and Therapy

Cited by 5

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

Ovarian cancer diagnosis and treatmentCancer Mechanisms and Therapy

Cited by 5